TY - JOUR
T1 - A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab
AU - Sawas, Ahmed
AU - Farber, Charles M.
AU - Schreeder, Marshall T.
AU - Khalil, Mazen Y.
AU - Mahadevan, Daruka
AU - Deng, Changchun
AU - Amengual, Jennifer E.
AU - Nikolinakos, Petros G.
AU - Kolesar, Jill M.
AU - Kuhn, John G.
AU - Sportelli, Peter
AU - Miskin, Hari P.
AU - O'Connor, Owen A.
N1 - Publisher Copyright:
© 2017 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - This phase 1/2 study evaluated the safety, pharmacokinetic behavior and anti-tumour activity of ublituximab, a unique type I, chimeric, glycoengineered anti-CD20 monoclonal antibody, in rituximab-relapsed or -refractory patients with B-cell non-Hodgkin lymphoma (B-NHL) or chronic lymphocytic leukaemia (CLL). Induction therapy (doses of 450–1200 mg) consisted of 4 weekly infusions in cycle 1 for NHL and 3 weekly infusions in cycles 1 and 2 for CLL. Patients received ublituximab maintenance monthly during cycles 3–5, then once every 3 months for up to 2 years. Enrolled patients with B-NHL (n = 27) and CLL (n = 8) had a median of 3 prior therapies. No dose-limiting toxicities or unexpected adverse events (AEs) occurred. The most common AEs were infusion-related reactions (40%; grade 3/4, 0%); fatigue (37%; grade 3/4, 3%); pyrexia (29%; grade 3/4, 0%); and diarrhoea (26%; grade 3/4, 0%). Common haematological AEs were neutropenia (14%; grade 3/4, 14%) and anaemia (11%; grade 3/4, 6%). The overall response rate for evaluable patients (n = 31) was 45% (13% complete responses, 32% partial responses). Median duration of response and progression-free survival were 9·2 months and 7·7 months, respectively. Ublituximab was well-tolerated and efficacious in a heterogeneous and highly rituximab-pre-treated patient population.
AB - This phase 1/2 study evaluated the safety, pharmacokinetic behavior and anti-tumour activity of ublituximab, a unique type I, chimeric, glycoengineered anti-CD20 monoclonal antibody, in rituximab-relapsed or -refractory patients with B-cell non-Hodgkin lymphoma (B-NHL) or chronic lymphocytic leukaemia (CLL). Induction therapy (doses of 450–1200 mg) consisted of 4 weekly infusions in cycle 1 for NHL and 3 weekly infusions in cycles 1 and 2 for CLL. Patients received ublituximab maintenance monthly during cycles 3–5, then once every 3 months for up to 2 years. Enrolled patients with B-NHL (n = 27) and CLL (n = 8) had a median of 3 prior therapies. No dose-limiting toxicities or unexpected adverse events (AEs) occurred. The most common AEs were infusion-related reactions (40%; grade 3/4, 0%); fatigue (37%; grade 3/4, 3%); pyrexia (29%; grade 3/4, 0%); and diarrhoea (26%; grade 3/4, 0%). Common haematological AEs were neutropenia (14%; grade 3/4, 14%) and anaemia (11%; grade 3/4, 6%). The overall response rate for evaluable patients (n = 31) was 45% (13% complete responses, 32% partial responses). Median duration of response and progression-free survival were 9·2 months and 7·7 months, respectively. Ublituximab was well-tolerated and efficacious in a heterogeneous and highly rituximab-pre-treated patient population.
KW - B-cell lymphoma
KW - LFB-R603
KW - TG-1101
KW - anti-CD20 monoclonal antibody
KW - ublituximab
UR - http://www.scopus.com/inward/record.url?scp=85013426789&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85013426789&partnerID=8YFLogxK
U2 - 10.1111/bjh.14534
DO - 10.1111/bjh.14534
M3 - Article
C2 - 28220479
AN - SCOPUS:85013426789
SN - 0007-1048
VL - 177
SP - 243
EP - 253
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 2
ER -